3 completed, 1 active not recruiting, 1 unknown, 1 withdrawn. 2 Not applicable, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Early Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Alzheimer disease type 1: new trials by email Literature Review of Alzheimer disease type 1 trials Research Report on Alzheimer disease type 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brain Health & the Microbiome Gut Microbiome Testing - Mild Cognitive Impairment, Mild Dementia | Completed | George Washington University | 44 | 2023-08-25 | 2026-01-29 | |
| Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease APH-1105, Placebo - Dementia, Alzheimer Disease 1 | Phase 2 | Unknown | Aphios | 60 | 2023-06-01 | 2021-07-27 |
| A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) Spectris™ AD - Active, Spectris™ AD - Sham - Alzheimer Disease, Alzheimer Disease 1 | Not applicable | Completed | Cognito Therapeutics, Inc. | 673 | 2022-12-13 | 2026-09-09 |
| Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy Aducanumab, Exablate Model 4000 Type 2, Lecanemab - Mild Cognitive Impairment, Alzheimer Disease 1 | Early Phase 1 | Active not recruiting | Ali Rezai | 15 | 2022-07-14 | 2026-01-22 |
| Progress of Mild Alzheimer's Disease in Participants on Acupuncture Versus Sham Acupuncture Active acupuncture, Sham acupuncture, Donepezil Hydrochloride - Alzheimer Disease 1 | Not applicable | Completed | Shanghai Institute of Acupuncture, Moxibustion and Meridian | 160 | 2022-06-30 | 2026-05-22 |
| A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease No Intervention - Alzheimer Disease, Alzheimer Disease 1 | Withdrawn | ProgenaBiome | 2020-03-02 | 2025-06-05 |
Alzheimer Disease (4) · Alzheimer disease type 2 (3) · Alzheimer disease, familial, type 3 (3) · Cognitive Dysfunction (3) · Alzheimer Disease 10 (2) · Alzheimer Disease 11 (2) · Alzheimer Disease 12 (2) · Alzheimer Disease 13 (2) · Alzheimer Disease 14 (2) · Alzheimer Disease 15 (2) · Alzheimer Disease 16 (2) · Alzheimer Disease 5 (2) · Alzheimer Disease 6 (2) · Alzheimer Disease 7 (2)
Mental Disorders (6) · Neurocognitive Disorders (6) · Brain Diseases (4) · Central Nervous System Diseases (4) · Nervous System Diseases (4) · Neurodegenerative Diseases (4) · Tauopathies (4) · Cognition Disorders (3) · Dementia (2) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
Donepezil (1) · aducanumab (1) · lecanemab (1)
Ali Rezai (1) · Aphios (1) · Cognito Therapeutics, Inc. (1) · George Washington University (1) · ProgenaBiome (1) · Shanghai Institute of Acupuncture, Moxibustion and Meridian (1)
United States (4) · China (1)
Ali Rezai, MD, FAANS (1) · Robbert Zusterzeel, MD, PhD, MPH (1) · Sabine Hazan, MD (1) · Xiaopeng Ma, MD, PhD (1)